Keywords
How to Cite
Abstract
Tibbiy foydalanish sohasida botulinotoksinining (BT) paydo bo'lishi bir qator kasalliklarni davolashda va estetik tibbiyotda inqilob qildi. Botulinum toksini paralitik/miorelaksant ta'sirga ega bo'lgan eng kuchli neyrotoksindir. Ushbu moddaning eng kuchli relaksatsiya xususiyatlari boshqa ma'lum usullar bilan samarali va doimiy tuzatishga qodir bo'lmagan patologik sharoitlarni davolash uchun muvaffaqiyatli qo'llaniladi. Pastki siydik yo'llarining ko'plab disfunksiyalari mushak tuzilmalarining tonusining oshishi yoki spazmlari bilan bog'liq bo'lib, ularni qovuq zonalariga BT ning aniq kiritilishi bilan tuzatish mumkin. Neyrogen haddan tashqari faol siydik pufagi uchun BT qo’llanishining samaradorligi va xavfsizligi keng ko'lamli ko'p markazli tadqiqotlarda o'rganildi va tasdiqlandi.
References
Montecucco C, Molgo J. Botulinal neurotoxins:revival of an old killer. Current option in pharmacology, 2005,
Frank JE. Historical notes on botulism.Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. 2004,
Aoki KR. Pharmacology and immunology of botulinum toxin. J Neurol, 2001.
Schiavo G, Santucci A, Dasgupta BR,. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOHterminal peptide bonds. FEBS Lett, 2006.
Purves D et al. Autonomic Regulation of the Bladder. Neuroscience. 2014.
Apostolidis A et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve bers following intra-detrusor injections of botulinum toxin for human detrusor overactivity. Eur Urol 2006.
Ботокс®*. Инструкция по медицинскому применению. / Botox®*. Instruction for use.
Schurch B, Stihrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Pleriminary results. J Urol, 2000, 164: 692.
Schurch B, Hauri D, . Botulinum A toxin as a treatment of detrusor-sphincter dyssinergia: a prospective study in 24 spinal cord injured patients. J Urol, 2012
Phelan MW, Franks M. Botulinum toxin urethral sphincter injection to restore bladder empting in men and women with voiding dysfunction. Urol, 2001,
Chancellor MB, Elovic E,.Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions. Toxicon, 2013.
Аполихин О.И., Ромих В.В.Рекомендации по ведению больных с нейрогенными нарушениями мочеиспускания.Экспериментальная и клиническая урология,2010, 1(3):
Сивков А.В., Ромих В.В. Симптомы нарушения функции нижних мочевых путей: уродинамические аспекты. Consilium Medicum, 2006,
Cruz F, Nitti V. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). Neurourology, 2014.
Abrams P, et al. eds. From the 5th ICI, Health Publication Ltd, 2013.
European Association of Urology. Guidelines on lower urinary tract dysfunction. 2009. http://www.uroweb.org/fileadmin/tx_eauguidelines/2022/
Lucas MG et al. EAU guidelines on urinary incontinence. 2012. Available from http://www.uroweb. org/gls/pdf/18 (Last accessed February 2013).
NICE guideline. Urinary incontinence in women: the management of urinary incontinence in women. Draft for consultation. Available from http://www.nice.org.uk/nicemedia/live/